Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AGER | Q15109 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [18F]Fluoromisonidazole SCHEMBL17022268 | 1.00 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| [18F]Fluoromisonidazole SCHEMBL13020421 | 1.00 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| [18F]Fluoromisonidazole SCHEMBL18401354 | 1.00 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL12396375 | 0.91 | KMT2A (0.78) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL368113 | 0.88 | KMT2A (0.59) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL16367339 | 0.88 | KMT2A (0.59) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL2358150 | 0.88 | KMT2A (0.71) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL16473558 | 0.86 | KMT2A (0.68) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL15899144 | 0.85 | KMT2A (0.56) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL8897223 | 0.85 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583881-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2026-03-24 | — | — | US | claimed |
| CN-120081908-A | Multifunctional probe based on protein dynamic combination and preparation and application thereof | 莎穆(上海)生物科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-20240350683-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | GE HEALTHCARE LIMITED (GB) | 2024-10-24 | — | — | US | claimed |
| US-20240059724-A1 | DEVICE AND CASSETTE FOR PERFORMING A PLURALITY OF SYNTHESIS PROCESSES OF PREPARING A RADIOPHARMACEUTICAL IN SERIES | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2024-02-22 | — | — | US | claimed |
| CN-117500773-A | Method for preparing [18F ] radiolabelled compounds with low water content during the labelling step | 通用电气健康护理有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117500525-A | preparation of pH-adjusted ascorbic acid solutions | 通用电气健康护理有限公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2024006901-A1 | USES OF BIPOLAR TRANS CAROTENOIDS IN THE TREATMENT OF CANCER | DIFFUSION PHARMACEUTICALS LLC (US) | 2024-01-04 | — | — | WO | claimed |
| CN-117222890-A | Analytical HPLC | 通用电气健康护理有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-109154671-B | Radioactivity detection | 赫尔大学 | 2022-10-04 | — | — | CN | claimed |
| US-20260144846-A1 | Modulation Of Tumor Immunity By Protein-Mediated O2 Delivery | OMNIOX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137789-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090353-A1 | METHODS AND RELATED ASPECTS FOR IDENTIFYING TUMOR SUBTYPES | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-3458037-B1 | FLUOROCHEMICAL TARGETED THERAPIES | MTM RES LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12583881-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2026-03-24 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| EP-2593796-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | Auckland Uniservices Limited (NZ) | 2013-05-22 | — | — | EP | disclosed |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| WO-2012008860-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011151320-A1 | NITROIMIDAZOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137789-A1 | BRUSH PRODRUGS AND USES THEREOF | ABCB11, SLC10A2, CES2 | KMT2A 1548/4885LMNA 796/4885THRB 650/4885 |
| US-20240350683-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | PROC, CYP27B1, TTPA | KMT2A 2797/4885LMNA 2353/4885THRB 4098/4885 |
| US-20260144846-A1 | Modulation Of Tumor Immunity By Protein-Mediated O2 Delivery | CD4, HIF1A, HIF1AN | KMT2A 2204/4885LMNA 1983/4885THRB 908/4885 |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | NISCH, CNDP2, MYADM | KMT2A 4229/4885LMNA 3487/4885THRB 3937/4885 |
| US-12583881-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | TMEM14C, FLT1, SLC6A12 | KMT2A 3017/4885LMNA 2083/4885THRB 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.